thyroid:  right lobe, isthmus, left lobe

A phase II study tests a new drug for patients with advanced thyroid cancer

Jan 24, 2017

A phase II trial of CUDC-907, a new drug that may be able to shrink thyroid tumors that have spread or gotten worse, is being tested in metastatic or advanced thyroid cancer.  Currently, there is no standard or effective treatment for the most aggressive types of thyroid cancer such as anaplastic and poorly differentiated thyroid cancer.  Learn more...

A phase II study tests a new drug for patients with advanced thyroid cancer

Dr. Alex Compton appointed as tenure track investigator

Jan 9, 2017

Alex Compton, Ph.D. has joined the HIV Dynamics and Replication Program (HIV DRP) as a tenure track Investigator.  Dr. Compton’s research is broadly focused on the antiviral innate immune response against HIV-1 infection. Learn more...

Dr. Frank Lin appointed as Lasker Clinical Research Scholar

Dec 28, 2016

Frank Lin, M.D. has joined the Molecular Imaging Program (MIP) as a Lasker Clinical Research Scholar.  Dr. Lin will perform pre-clinical and clinical research in the use of targeted radionuclide therapy (tRNT). Learn more...

Roberto Weigert produces Celldance video for ASCB 2016 Annual Meeting

Dec 7, 2016

Roberto Weigert, Senior Investigator in the Laboratory of Cellular and Molecular Biology, created one of the top-three videos for American Society for Cell Biology’s Celldance 2016. The theme for this year’s videos is “Tell your own cell story.” Weigert’s lab created, “Discovery Inside Living Cells in Multicellular Organisms.” He describes the video as every cell biologist’s dream of watching living cells work in living tissue as they keep the body alive. The video premiered during the ASCB 2016 Annual Meeting.

Dr. Terri Armstrong appointed as senior investigator

Nov 29, 2016

Terri Armstrong, Ph.D. has joined the Neuro-Oncology Branch as a Senior Investigator.  Dr. Armstrong's work is focused on improving the assessment of patient outcomes measures and their incorporation into clinical trials.  She is also exploring the clinical phenotypes and genotypes associated with significant symptoms as well as the underlying biologic correlates of both symptoms and toxicity with the goal of developing interventions to improve patient outcomes.  Learn more…

Dr. Jagan Muppidi appointed as tenure track investigator

Nov 29, 2016

Jagan Muppidi, M.D., Ph.D., has joined the Lymphoid Malignancies Branch as a Stadtman Tenure Track Investigator. Dr. Muppidi will develop an independent research program centered on mechanisms of lymphomagenesis and collaborate on clinical investigations into the treatment of lymphoma.  Learn more...

Dr. Pedro Jorge Batista appointed as tenure track investigator

Nov 28, 2016

Pedro Jorge Batista has been appointed as a Stadtman Tenure Track Investigator in the Laboratory of Cell Biology.  Dr. Batista's research focuses on the determination of the effect of RNA modifications on RNA biogenesis and function and the underlying mechanisms of why RNA molecules are modified, or how these modifications affect RNA maturation and function.

Dr. Merlino elected as AAAS Fellow

Nov 28, 2016

The American Association for the Advancement of Science recently elected 391 members as Fellows of AAAS. Election as a Fellow honors members whose efforts on behalf of the advancement of science or its applications in service to society have distinguished them among their peers and colleagues.  We wish to congratulate Dr. Glenn Merlino, CCR Scientific Director for Basic Research and Co-Chief in the Laboratory of Cancer Biology and Genetics, on being elected as a member of the 2016 class of AAAS Fellows in the section on Biological Sciences!

Brigitte C. Widemann, M.D.

Brigitte Widemann selected as Chief, Pediatric Oncology Branch

Nov 18, 2016

Dr. Brigitte Widemann has been selected as chief of CCR's Pediatric Oncology Branch. Widemann is a world-renowned leader in the development of early clinical trials for children and young adults with refractory cancers and genetic tumor predisposition syndromes. She and her colleagues have developed novel imaging methods for NF1-related plexiform neurofibromas and pioneered the development of early phase drug treatments for this patient population. CCR's Director, Tom Misteli, called Widemann "an incisive clinical researcher, compassionate physician and inspiring leader."  In October, she received the Humanitarian Award from the Children's Tumor Foundation.

Brigitte C. Widemann, M.D.

Brigitte Widemann receives Humanitarian Award at Children’s Tumor Foundation Gala

Oct 19, 2016

Acting Chief of the Pediatric Oncology Branch and Senior Investigator Brigitte Widemann received the Humanitarian Award last night at the 2016 New York Gala for the Children’s Tumor Foundation. The award is the foundation’s highest honor and is given to individuals who have had a positive impact on people living with neurofibromatosis (NF) and who are working to end NF through research.